Clinical pharmacology of the new COMT inhibitor CGP 28 014
- 1 November 1993
- journal article
- Published by Springer Nature in Neurochemical Research
- Vol. 18 (11) , 1163-1167
- https://doi.org/10.1007/bf00978368
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Dopamine-derived tetrahydroisoquinolines and Parkinson's disease.1993
- Biosynthesis of salsolinol, a tetrahydroisoquinoline alkaloid, in healthy subjectsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1990
- Effects of the COMT inhibitor, CGP 28014, on plasma homovanillic acid and O-methylation of exogenous L-DOPA in the ratPublished by Springer Nature ,1990
- Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjectsPublished by Springer Nature ,1990
- Influence of food intake on the enantiomeric composition of urinary salsolinol in manJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- New selective COMT inhibitors: useful adjuncts for Parkinson's disease?Trends in Pharmacological Sciences, 1989
- Inhibition of Catechol‐O‐Methyltransferase by 6,7‐Dihydroxy‐3,4‐Dihydroisoquinolines Related to Dopamine: Demonstration Using Liquid Chromatography and a Novel Substrate for O‐MethylationJournal of Neurochemistry, 1987
- Electrochemical detection of catecholamines in urine and plasma after separation with HPLCClinica Chimica Acta; International Journal of Clinical Chemistry, 1984
- Determination of nine catecholamine metabolites and 5-hydroxyindolacetic acid in urine by capillary gas chromatographyJournal of Chromatography A, 1983
- Selective 7-O-methylation of salsolinol in rat brain and heart in vivoLife Sciences, 1980